menu
    • menu
    [{"orgOrder":0,"company":"Sino Biopharmaceutical","sponsor":"LaNova Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"LM-302","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Sino Biopharmaceutical","amount2":0.94999999999999996,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.94999999999999996,"dosageForm":"Injection","sponsorNew":"Sino Biopharmaceutical \/ LaNova Medicines","highestDevelopmentStatusID":"10","companyTruncated":"Sino Biopharmaceutical \/ LaNova Medicines"},{"orgOrder":0,"company":"Sino Biopharmaceutical","sponsor":"LaNova Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Series C Financing","leadProduct":"Apatinib","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Sino Biopharmaceutical","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Sino Biopharmaceutical \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sino Biopharmaceutical \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"Sino Biopharmaceutical","sponsor":"Inventiva Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Lanifibranor","moa":"Peroxisome proliferator-activated receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sino Biopharmaceutical","amount2":0.31,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.31,"dosageForm":"Tablet","sponsorNew":"Sino Biopharmaceutical \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sino Biopharmaceutical \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"Sino Biopharmaceutical","sponsor":"Inventiva Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"Peroxisome proliferator-activated receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sino Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sino Biopharmaceutical \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sino Biopharmaceutical \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"Sino Biopharmaceutical","sponsor":"Akeso","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Penpulimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sino Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sino Biopharmaceutical \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Sino Biopharmaceutical \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"Sino Biopharmaceutical","sponsor":"Treadwell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"CFI-400945","moa":"||Serine\/threonine-protein kinase PLK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sino Biopharmaceutical","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Sino Biopharmaceutical \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Sino Biopharmaceutical \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"Sino Biopharmaceutical","sponsor":"Sinovac Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Funding","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sino Biopharmaceutical","amount2":0.5,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.5,"dosageForm":"Injection","sponsorNew":"Sino Biopharmaceutical \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Sino Biopharmaceutical \/ Sino Biopharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Sino Biopharmaceutical

    Menu

    Sino Biopharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LM-302

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : LaNova Medicines

                            Deal Size : $951.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sino Biopharmaceutical to Acquire LaNova Medicines for up to $951 million

                            Details : Upon completion of the acquisition, LaNova will become a wholly owned subsidiary of Sino. Its lead product, LM-302, is being evaluated for the treatment of CLDN18.2-positive gastric cancer.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            July 15, 2025

                            Lead Product(s) : LM-302

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : LaNova Medicines

                            Deal Size : $951.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LM-302,Apatinib,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : LaNova Medicines

                            Deal Size : $42.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            LaNova Initiates Phase 1 for LM-299 Anti-PD-1/VEGF Antibody and $42M Financing

                            Details : The financing is intended to support the clinical development of LM-302, an anti-CLDN 18.2 ADC, which is currently in late-stage clinical trials in China for the treatment of gastric cancers.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            October 18, 2024

                            Lead Product(s) : LM-302,Apatinib,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : LaNova Medicines

                            Deal Size : $42.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanifibranor

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase III

                            Recipient : Inventiva Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Inventiva Announces that its Partner Sino Biopharm Received IND Approval from the NMPA to initiate Clinical Tr...

                            Details : IVA337 (Lanifibranor), is an orally-available small molecule which induces anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three PPAR isoforms, regulating gene expression.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 25, 2023

                            Lead Product(s) : Lanifibranor

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase III

                            Recipient : Inventiva Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanifibranor

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase III

                            Recipient : Inventiva Pharma

                            Deal Size : $307.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Inventiva and Sino Biopharm Announce Licensing and Collaboration Agreement to Develop and Commercialize Lanifi...

                            Details : Lanifibranor (IVA337), is an orally-available small molecule with breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) following a positive Phase IIb trial in patients with non-alcoholic steatohepatitis (NASH).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $12.0 million

                            September 21, 2022

                            Lead Product(s) : Lanifibranor

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase III

                            Recipient : Inventiva Pharma

                            Deal Size : $307.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CFI-400945,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Treadwell Therapeutics

                            Deal Size : $91.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Treadwell Therapeutics Announces The Closing of a $91 Million Series B Financing

                            Details : Proceeds will fund the continued clinical development of CFI-400945, CFI-402257 and CFI-402411, the preclinical development of the Biologics and Cell Therapy platform, as well as general corporate purposes.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 18, 2021

                            Lead Product(s) : CFI-400945,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Treadwell Therapeutics

                            Deal Size : $91.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Penpulimab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Akeso

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China

                            Details : Penpulimab is currently the only new PD-1 monoclonal antibody that applies IgG1 subtype and is modified by Fc segment, which has a lower antigen binding dissociation rate and a unique binding epitope as demonstrated by analysis on crystal structure.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 05, 2021

                            Lead Product(s) : Penpulimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Akeso

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inactivated Vero Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Sinovac Biotech

                            Deal Size : $500.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Sinovac Secures Approximately $500 Million in Funding for COVID-19 Vaccine Development

                            Details : The investment deal comes as Sinovac expands supply deals and trials of its experimental COVID-19 vaccine CoronaVac with more countries following positive results from early to mid-stage clinical trials.

                            Product Name : CoronaVac

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            December 07, 2020

                            Lead Product(s) : Inactivated Vero Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Sinovac Biotech

                            Deal Size : $500.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth